AU2001265840A1 - Use of potassium channel agonists for reducing fat food comsumption - Google Patents

Use of potassium channel agonists for reducing fat food comsumption

Info

Publication number
AU2001265840A1
AU2001265840A1 AU2001265840A AU6584001A AU2001265840A1 AU 2001265840 A1 AU2001265840 A1 AU 2001265840A1 AU 2001265840 A AU2001265840 A AU 2001265840A AU 6584001 A AU6584001 A AU 6584001A AU 2001265840 A1 AU2001265840 A1 AU 2001265840A1
Authority
AU
Australia
Prior art keywords
comsumption
potassium channel
reducing fat
fat food
channel agonists
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2001265840A
Inventor
Christina Bjenning
John Bondo Hansen
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Novo Nordisk AS
Original Assignee
Novo Nordisk AS
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Novo Nordisk AS filed Critical Novo Nordisk AS
Publication of AU2001265840A1 publication Critical patent/AU2001265840A1/en
Abandoned legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/549—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame having two or more nitrogen atoms in the same ring, e.g. hydrochlorothiazide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/54—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame
    • A61K31/542—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one sulfur as the ring hetero atoms, e.g. sulthiame ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
    • C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
    • C07D513/04—Ortho-condensed systems
AU2001265840A 2000-06-26 2001-06-25 Use of potassium channel agonists for reducing fat food comsumption Abandoned AU2001265840A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
DKPA200000987 2000-06-26
DKPA200000987 2000-06-26
PCT/DK2001/000443 WO2002000223A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for reducing fat food comsumption

Publications (1)

Publication Number Publication Date
AU2001265840A1 true AU2001265840A1 (en) 2002-01-08

Family

ID=8159577

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2001265840A Abandoned AU2001265840A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for reducing fat food comsumption
AU2001265839A Abandoned AU2001265839A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for the treatment of cancer

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2001265839A Abandoned AU2001265839A1 (en) 2000-06-26 2001-06-25 Use of potassium channel agonists for the treatment of cancer

Country Status (3)

Country Link
US (2) US20020035106A1 (en)
AU (2) AU2001265840A1 (en)
WO (2) WO2002000222A1 (en)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2004005299A1 (en) * 2002-07-04 2004-01-15 Novo Nordisk A/S Polymorphic forms of a 4h-thieno[3,2-e]-1,2,4-thiadiazine 1,1-dioxide derivative
DE102004029909A1 (en) 2004-06-21 2006-01-19 Roche Diagnostics Gmbh Method and device for the preparation of bindable reagent carriers
WO2006026469A2 (en) 2004-08-25 2006-03-09 Essentialis, Inc. Pharmaceutical formulations of potassium atp channel openers and uses thereof
US7705010B2 (en) * 2005-02-22 2010-04-27 Cedars-Sinai Medical Center Use of minoxidil sulfate as an anti-tumor drug
US20080188480A1 (en) * 2005-02-22 2008-08-07 Cedars-Sinai Medical Center Use of Sildenafil, Vardenafil and Other 5-Phosphodiesterase Inhibitors to Enhance Permeability of the Abnormal Blood-Brain Barrier
US9757384B2 (en) 2005-04-06 2017-09-12 Essentialis, Inc. Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
EP3545958A1 (en) * 2006-01-05 2019-10-02 Essentialis, Inc. Salts of potassium atp channel openers and uses thereof
EP1884774A1 (en) * 2006-08-03 2008-02-06 INSERM (Institut National de la Santé et de la Recherche Medicale) A method for the in vitro screening of anti-cancer compounds that inhibits SK3 activity, and said anti-cancer compounds
AU2008272923A1 (en) * 2007-07-02 2009-01-08 Essentialis, Inc. Salts of potassium ATP channel openers and uses thereof
US8937042B2 (en) 2007-11-16 2015-01-20 Novo Nordisk A/S Pharmaceutical compositions comprising GLP-1 peptides or extendin-4 and a basal insulin peptide
WO2009099820A2 (en) * 2008-02-01 2009-08-13 Mayo Foundation For Medical Education And Research Modulating body weight
TWI383754B (en) * 2008-07-18 2013-02-01 Tci Co Ltd Food pastille
EP2819675A4 (en) 2012-02-27 2015-07-22 Essentialis Inc Salts of potassium atp channel openers and uses thereof
ES2806977T3 (en) 2014-11-14 2021-02-19 Essentialis Inc Methods for treating subjects with Prader-Willi syndrome or Smith-Magenis syndrome
CA2971413A1 (en) 2014-12-16 2016-06-23 Axovant Sciences Gmbh Geminal substituted quinuclidine amide compounds as agonists of alpha-7 nicotinic acetylcholine receptors
MX2017016231A (en) 2015-06-10 2018-11-29 Axovant Sciences Gmbh Aminobenzisoxazole compounds as agonists of a7-nicotinic acetylcholine receptors.
US10428062B2 (en) 2015-08-12 2019-10-01 Axovant Sciences Gmbh Geminal substituted aminobenzisoxazole compounds as agonists of α7-nicotinic acetylcholine receptors
CN106518804A (en) * 2016-07-31 2017-03-22 北京梅尔森医药技术开发有限公司 Novel crystal form of diazoxide and preparation method thereof
US11357841B2 (en) * 2017-01-06 2022-06-14 Iovance Biotherapeutics, Inc. Expansion of tumor infiltrating lymphocytes with potassium channel agonists and therapeutic uses thereof

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1420780A (en) * 1972-03-22 1976-01-14 V N I Khim Farmatsevtichesky I Medicinal preparation of treatment of malignant neoplasms mostly hemoblastoses and chorionepithelioma
US5284845A (en) * 1991-03-14 1994-02-08 Paulsen Elsa P Use of oral diazoxide for the treatment of disorders in glucose metabolism
AU7733896A (en) * 1995-11-13 1997-06-05 Brandeis University Regulation of cancer-causing tyrosine kinases by potassium ion conductance
PL327938A1 (en) * 1996-01-17 1999-01-04 Novo Nordisk As Derivatives of 1,2,4-thiadiazine and 1,4-thiazine, their production and application
WO1997026264A1 (en) * 1996-01-17 1997-07-24 Novo Nordisk A/S Pyrido-1,2,4-thiadiazine and pyrido-1,4-thiazine derivatives, their preparation and use
US6242443B1 (en) * 1996-06-21 2001-06-05 Novo Nordisk Ais 1,2,4-benzothiadiazine derivatives, their preparation and use
HUP0003999A3 (en) * 1997-07-16 2003-03-28 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation, their use and pharmaceutical compositions containing them
AU1751299A (en) * 1997-12-19 1999-07-12 Novo Nordisk A/S Fused 1,2,4-thiadiazine derivatives, their preparation and use
JP2000143539A (en) * 1998-11-05 2000-05-23 Hsp Kenkyusho:Kk Agent for suppressing expression of endoplasmic reticulum chaperone gene
AU1648600A (en) * 1998-12-04 2000-06-26 Neurosearch A/S Use of isatin derivatives as ion channel activating agents
IL143402A0 (en) * 1998-12-18 2002-04-21 Novo Nordisk As Fused 1,2,4-thiadiazine derivatives, their preparation and use
GB9915414D0 (en) * 1999-07-01 1999-09-01 Glaxo Group Ltd Medical use

Also Published As

Publication number Publication date
WO2002000222A1 (en) 2002-01-03
WO2002000223A1 (en) 2002-01-03
US20020028808A1 (en) 2002-03-07
AU2001265839A1 (en) 2002-01-08
US20020035106A1 (en) 2002-03-21

Similar Documents

Publication Publication Date Title
AU2001265840A1 (en) Use of potassium channel agonists for reducing fat food comsumption
AU2001249967A1 (en) Composition and methods for tissue preservation
AU2002348283A1 (en) Additive solution for blood preservation
IL158131A0 (en) Methods, compounds, and compositions for reducing body fat and modulating fatty acid metabolism
HUP0101269A3 (en) Potassium channel inhibitors
AU2001245704A1 (en) High performance carburizing stainless steel for high temperature use
AU2003251557A1 (en) Fat compositions for infant formula and methods therefor
AU2002366804A1 (en) Methods to reduce body fat
GB2383936B (en) Food additive composition
AU2003259112A8 (en) Enzymatic process for the preparation of foods, feedstuffs and ingredients therefor
AU4411399A (en) Potassium channel inhibitors
AU2002337135A1 (en) Compounds for reducing excessive intake of food
GB0118188D0 (en) Ice cream holder
AU2001250443A1 (en) Food composition
AU4686701A (en) Method and device for freezing food
IL159815A0 (en) Biscuit for frozen confectionery
AU2002249809A1 (en) Potassium channel inhibitors
AU2002227198A1 (en) Reduced fat lipid-based fillings
AU2001282041A1 (en) Dietetic food for breaking down fat
AU2002227197A1 (en) Reduced saturated fat lipid-based fillings
AU2001265841A1 (en) Use of potassium channel openers for the treatment of insulitis
AU2002337303A1 (en) Estimation of channel parameters using re-encoding
AU2001253163A1 (en) Kiosk with body fat analyzer
AU2001285767A1 (en) Use of azoxystrobin for preservation of foodstuffs
EP1077705A4 (en) Potassium channel agonists

Legal Events

Date Code Title Description
MK6 Application lapsed section 142(2)(f)/reg. 8.3(3) - pct applic. not entering national phase
TH Corrigenda

Free format text: IN VOL 16, NO 12, PAGE(S) 2688-2711 UNDER THE HEADING APPLICATIONS LAPSED, REFUSED OR WITHDRAWN PLEASE DELETE ALL REFERENCE TO APPLICATION NO. 45353/00, 78995/00, 56595/01, 65839/01, 65840/01, 66300/01, 13576/02